1. Home
  2. FNWB vs MDXH Comparison

FNWB vs MDXH Comparison

Compare FNWB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Northwest Bancorp

FNWB

First Northwest Bancorp

HOLD

Current Price

$8.60

Market Cap

79.8M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.19

Market Cap

183.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWB
MDXH
Founded
1923
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
79.8M
183.4M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
FNWB
MDXH
Price
$8.60
$3.19
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$13.50
$7.67
AVG Volume (30 Days)
27.4K
102.2K
Earning Date
04-23-2026
02-26-2026
Dividend Yield
0.81%
N/A
EPS Growth
36.00
N/A
EPS
N/A
N/A
Revenue
$176,000.00
N/A
Revenue This Year
$19.24
$30.78
Revenue Next Year
$8.90
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.05
$1.36
52 Week High
$10.98
$5.33

Technical Indicators

Market Signals
Indicator
FNWB
MDXH
Relative Strength Index (RSI) 26.83 38.45
Support Level $8.16 $3.05
Resistance Level $9.00 $3.78
Average True Range (ATR) 0.30 0.14
MACD -0.04 -0.01
Stochastic Oscillator 21.66 11.49

Price Performance

Historical Comparison
FNWB
MDXH

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: